Condition

PDAC - Pancreatic Ductal Adenocarcinoma clinical trials and research

• 25Clinical trials
• 1New in 30 days
• 24Countries

Newest PDAC - Pancreatic Ductal Adenocarcinoma clinical trials

All recruiting trials (25)

• AI-assisted 4D PET imaging to detect early pancreatic cancer lesions

  This study tests whether AI-assisted 4D long-axial PET imaging with FDG and FAPI can help detect early PDAC lesions in patients with suspected pancreatic tumors.

  Recruiting Ruijin Hospital · Shanghai · NCT07925125

• Zoldonrasib plus Daraxonrasib vs Gemcitabine and Nab-Paclitaxel as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This study tests whether two investigational RAS inhibitors together can improve outcomes compared with standard chemotherapy in adults with newly diagnosed metastatic pancreatic cancer carrying the KRAS G12D mutation.

  Recruiting at 6 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 5 other locations · NCT07805954

• Biophotonic blood test to spot pancreatic cancer risk in at‑risk adults

  A blood test using light-based technology is being tested to see if it can predict pancreatic cancer development in people at risk, and also check how well treatments work for those affected.

  Recruiting Fondazione Policlinico Universitario Campus Bio-Medico · Rome, Italy · NCT07659639

• Zoldonrasib + chemotherapy vs placebo + chemotherapy as first-line treatment for metastatic KRAS G12D pancreatic cancer

  This trial tests whether adding zoldonrasib to standard chemotherapy helps people with newly diagnosed metastatic KRAS G12D pancreatic cancer.

  Recruiting at 25 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 24 other locations · NCT07621718

• Atebimetinib plus gemcitabine and nab‑paclitaxel as first‑line treatment for metastatic pancreatic cancer

  This trial will test whether adding the MAPK pathway drug atebimetinib to gemcitabine and nab‑paclitaxel helps people with newly diagnosed metastatic pancreatic ductal adenocarcinoma live longer.

  Recruiting at 76 sites Phase 3 Immuneering Corporation · Huntsville, Alabama and 75 other locations · NCT07562152

• Personalised Functional Profiling in colorectal cancer and pancreatic cancer

  This study tests a personalized drug-profiling approach using patient tumors to see if lab drug responses match actual patient outcomes in colorectal cancer and pancreatic cancer.

  Recruiting Luxembourg Institute of Health · Luxembourg, Luxembourg · NCT07500259

• Daraxonrasib alone or with gemcitabine and nab-paclitaxel for first-line metastatic pancreatic cancer

  This trial will see if daraxonrasib, alone or with gemcitabine and nab-paclitaxel, helps people with newly diagnosed metastatic pancreatic cancer live longer or slow tumor growth compared with standard gemcitabine and nab-paclitaxel.

  Recruiting at 61 sites Phase 3 Revolution Medicines, Inc. · Phoenix, Arizona and 81 other locations · NCT07491445

• AVA6103 for advanced or metastatic FAP-positive solid tumors

  This study will test whether the experimental IV drug AVA6103 is safe and can help adults with advanced or metastatic FAP-positive cancers such as pancreatic, gastric/GEJ, cervical, or vulvar adenocarcinomas.

  Recruiting at 7 sites Phase 1 Avacta Life Sciences Ltd · Scottsdale, Arizona and 6 other locations · NCT07454642

• Preventing complications after high-risk Whipple (pancreatoduodenectomy) with hydrocortisone, octreotide, and a teres ligament patch

  This tests whether giving hydrocortisone and octreotide around surgery plus placing a teres ligament patch can lower major complications after Whipple surgery in patients with a small pancreatic duct.

  Recruiting Phase 4 Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Amsterdam · NCT07262957

• Daraxonrasib after surgery for resected pancreatic ductal adenocarcinoma (PDAC)

  This trial tests whether taking daraxonrasib after surgery can help prevent cancer from coming back in adults with resected PDAC who completed perioperative chemotherapy.

  Recruiting at 85 sites Phase 3 Revolution Medicines, Inc. · Birmingham, Alabama and 85 other locations · NCT07252232

• Breath test to detect pancreatic ductal adenocarcinoma (VAPOR2)

  This research will try a non-invasive breath test that looks for volatile organic compounds to see if it can detect pancreatic cancer in adults referred from primary care with possible pancreatic symptoms.

  Recruiting Imperial College London · London · NCT07243262

• AI-enhanced low-dose CT to screen for pancreatic cancer

  This project will test whether an AI tool called PANDA can read low-dose CT scans to find early pancreatic cancer in people aged 50 and older.

  Recruiting at 5 sites Changhai Hospital · Shanghai, Shanghai Municipality and 4 other locations · NCT07117045

• EDV nanocell therapy with gemcitabine and nab‑paclitaxel for metastatic pancreatic cancer

  This trial tests whether adding EDV nanocell therapy (E-EDV-D682 with EDV-GC) to gemcitabine and nab‑paclitaxel helps people with metastatic pancreatic ductal adenocarcinoma who progressed after first-line therapy.

  Recruiting at 3 sites Phase 1/2 Engeneic Pty Limited · El Segundo, California and 3 other locations · NCT07049055

• Digital information and support app for people starting neoadjuvant therapy for pancreatic cancer

  This pilot will test whether the PDAC-PATHWAYS app is feasible and acceptable for people starting neoadjuvant therapy for pancreatic ductal adenocarcinoma.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT07047807

• TNG462 combined with RAS inhibitors or chemotherapy for MTAP‑loss pancreatic and RAS‑mutant lung cancer

  This trial will test whether taking oral TNG462 together with RAS inhibitors or standard chemotherapy is safe and helps people with MTAP‑loss pancreatic cancer or RAS‑mutant non‑small cell lung cancer.

  Recruiting at 18 sites Phase 1/2 Tango Therapeutics, Inc. · Scottsdale, Arizona and 17 other locations · NCT06922591

• BBO-11818 treatment for adults with KRAS mutant cancer

  This study is testing a new drug called BBO-11818 to see if it can help adults with certain types of cancer that have specific KRAS mutations.

  Recruiting at 17 sites Phase 1 TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Los Angeles, California and 16 other locations · NCT06917079

• Investigating ALTA3263 for advanced solid tumors with KRAS mutations

  This study is testing a new oral medication called ALTA3263 to see if it is safe and effective for adults with advanced solid tumors that have KRAS mutations.

  Recruiting at 14 sites Phase 1 Alterome Therapeutics, Inc. · Orlando, Florida and 13 other locations · NCT06835569

• Personalised organoid profiling from biopsy for pancreatic cancer

  This project will try to grow and test mini‑tumors (organoids) from echo‑endoscopic fine‑needle biopsies to help guide treatment for people with suspected pancreatic ductal adenocarcinoma.

  Recruiting at 2 sites IHU Strasbourg · Strasbourg and 1 other locations · NCT06666803

• Registry for patients at high risk for pancreatic cancer

  This study is creating a registry for people at high risk of pancreatic cancer to see if new tests can help catch the disease early.

  Recruiting Mayo Clinic · Rochester, Minnesota · NCT06151223

• Screening for pancreatic cancer in high-risk individuals

  This study is testing if combining blood tests and symptom checks with regular screenings can help find pancreatic cancer earlier in people who are at higher risk because of their genetics.

  Recruiting Early Phase 1 Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06122896

• Registry for young adults diagnosed with pancreatic cancer

  This study is gathering information from young adults diagnosed with pancreatic cancer to help improve future treatments and understand how this disease affects them.

  Recruiting Azienda Ospedaliera Universitaria Integrata Verona · Verona · NCT05845801

• Breath test for early detection of pancreatic cancer

  This study is testing a new breath test to see if it can help find pancreatic cancer earlier in patients.

  Recruiting Imperial College London · London · NCT05727020

• Combining surufatinib and camrelizumab with chemotherapy for advanced pancreatic cancer

  This study is testing a new combination of treatments for people with advanced pancreatic cancer to see if it works better than the standard options.

  Recruiting Phase 1/2 Chinese PLA General Hospital · Beijing · NCT05218889

• Managing glucose levels in pancreatic cancer patients

  This study is testing if closely managing blood sugar levels can help people with pancreatic cancer who are receiving standard chemotherapy feel better and improve their treatment outcomes.

  Recruiting at 2 sites British Columbia Cancer Agency · Vancouver, British Columbia and 1 other locations · NCT05132244

• Evaluating TJ033721 for advanced or metastatic solid tumors

  This study is testing a new drug called TJ033721 to see if it can help people with advanced or metastatic solid tumors, both on its own and in combination with other treatments.

  Recruiting at 7 sites Phase 1 I-Mab Biopharma US Limited · Orange, California and 20 other locations · NCT04900818

Related topics

Quick answers

How many PDAC - Pancreatic Ductal Adenocarcinoma clinical trials are recruiting right now?

25, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 24 countries. The most sites are in United States (14 trials), United Kingdom (6 trials), Italy (5 trials), China (4 trials), Australia (3 trials). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 3: 5, Phase 1: 4, Phase 1/2: 3, Phase 4: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →